CYP3A5 and CYP3A7 Genetic Polymorphisms Affect Tacrolimus Concentration in Pediatric Patients with Nephrotic Range Proteinuria

Liu Hongxia,Xu Qinxia,Huang Wenyan,Zhao Qi,Jiang Zhihu,Kuang Xinyu,Li Zhiling,Sun Huajun,Qiu Xiaoyan

DOI: https://doi.org/10.1007/s00228-019-02726-w

2019-01-01

European Journal of Clinical Pharmacology

Abstract:The original publication of this paper contains two errors. We apologize for any inconvenience this may have caused.

What problem does this paper attempt to address?

Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome.

Lingfei Huang,Junyan Wang,Jufei Yang,Huifen Zhang,Yinghua Ni,Zhengyi Zhu,Huijuan Wang,Peng Gao,Yuanyuan Wu,Jianhua Mao,Luo Fang

DOI: https://doi.org/10.2217/pgs-2019-0090

2019-01-01

Pharmacogenomics

Abstract:Aim: To evaluate the impact of CYP3A4*1G, CYP3A5*3 and ABCB1-C3435T polymorphisms on tacrolimus concentrations, efficacy and tolerance in pediatric primary nephrotic syndrome. Methods: Dose-adjusted concentrations (C-0/D), daily dose, frequency and time to relapse, cumulative remission days, and adverse reactions in 65 Chinese patients with various genotypes were retrospectively collected and compared. Results: C-0/D increased in CYP3A4*1/*1, CYP3A5*3/*3 and CYP3A4*1/*1-3A5*3/*3 diplotype carriers by 38.4, 69.7 and 40.9% compared with CYP3A4*1/*1G, CYP3A5*1/*3 and noncarriers, respectively. Recurrence risks were decreased in CYP3A4*1/*1 (0.43 of hazard ratio to *1/*1G) and CYP3A5*3/*3 carriers (0.43 of hazard ratio to *1/*3). None of polymorphisms was linked to adverse reactions. Conclusion: The genotypes of CYP3A4*1G and CYP3A5*3 rather than ABCB1-C3435T potentially predicted tacrolimus exposure and clinical response in pediatric primary nephrotic syndrome.
Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

Xin-min Nie,Rong Gui,Hong-shan Zhao,Da-long Ma,Deng-qing Li,Hong Yuan,Zu-fa Huang

DOI: https://doi.org/10.1007/s11771-005-0419-9

2005-01-01

Journal of Central South University of Technology

Abstract:Objective Tacrolimus is an immunosuppressive drug with narrow therapeutic range and wide interindividual variation in its pharmacokinetics. Tacrolimus is a substrate of cytochrome P450(CYP)3A5. The aim of this study was to evaluate whether the A6986G polymorphism is associated with tacrolimus concentration /dose ratio. Methods Fifty-two Chinese renal transplant patients were enrolled in this study. Their body weight, dosage and concentration of tacrolimus were observed. CYP3A5 genotype was determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis. Results A significant association was found between tacrolimus levels per dose/kg/d and CYP3A5 gene A6986G polymorphism ( P <0.001). The CYP3A5 * 3 * 3 patients have a significantly higher tacrolimus level/dose than CYP3A5 * 1 * 1 and CYP3A5 * 1 * 3. Conclusions CYP3A5 gene A6986G polymorphism is associated with tacrolimus pharmacokinetics and dose requirements. Pharmacogenetic methods could be employed prospectively to help the dose selection and to individualize immunosuppressive therapy according to the result.
Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis

Qiufen Xie,Qian Xiang,Zhiyan Liu,Guangyan Mu,Shuang Zhou,Zhuo Zhang,Lingyue Ma,Yimin Cui

DOI: https://doi.org/10.2174/1389200222666210825160021

Abstract:Background: Although the pharmacokinetic variability of Tacrolimus (Tac) metabolism is primarily influenced by CYP3A5 genotypes, the potential effect according to CYP3A5 polymorphisms in Tac extended-release (Tac-ER) and immediate-release (Tac-IR) and between these formulations' conversion needs further investigation. The purpose of this study was to clarify the association of CYP3A5 genotypes and pharmacokinetics of different Tac formulations in renal transplant recipients. Methods: PubMed, EMBASE, and Cochrane Library databases were searched for eligible studies (protocol registration No. CRD 42019133790 in PROSPERO network). The summary weighted mean difference with 95% confidence intervals was calculated for pharmacokinetic parameters using the random-effects model according to posttransplantation periods, genotypes and formulations. Sensitivity analysis, publication bias, and subgroup analyses were conducted. Results: A total of 27 studies involving 2,713 renal transplant recipients were adopted. Whether patients treated with Tac-ER or Tac-IR, CYP3A5 non-expressors (*3/*3) had a decreased daily dose and CL/F, an increased Ctrough, Ctrough/D, AUC0-24h/D and Cmax/D than expressors (*1/*1 or *1/*3) at most post-transplantation periods. Furthermore, when 1:1 dose conversion from Tac-IR to Tac-ER (all at ≥12 months post-transplantation), Ctrough and Cmax were decreased in both CYP3A5 non-expressors and expressors, while daily dose was only decreased in CYP3A5 nonexpressors and AUC0-24h was only decreased in CYP3A5 expressors. Finally, subgroup analyses indicated that ethnicity, mean age, and male percentage influenced daily dose and Ctrough of Tac, especially for Tac-IR. Conclusion: The results indicated that CYP3A5 genotypes affect the pharmacokinetics of Tac in renal transplant recipients in both formulations and between formulations' conversion. Future studies should be exploring more other associations of CYP3A5 genotypes and the pharmacodynamics of Tac.
Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

XU Fang,MA Lu-lin,FU Yan,ZHANG Ting,HU Yong-fang

DOI: https://doi.org/10.3969/j.issn.1001-6821.2008.03.004

2008-01-01

Abstract:Objective To investigate the association between CYP 3A5*3 genetic polymorphism and tacrolimus dose-adjusted concentration at 2 hours after administration (C2/dose). Methods CYP 3A5*3 genotype were analyzed by polymerase chain reaction restriction fragment length polymorphism in 61 Chinese renal transplant recipients receiving tacrolimus. Microparticle enzyme immunoassay was used to measure the whole blood concentration of tacrolimus. Tacrolimus dosage,C2 and C2/dose were determined at 1 week, 1 month, and 3 months after transplantation.Results There was no significant difference of tacrolimus dosage between CYP 3A5*1/*1+CYP 3A5*1/*3 group and CYP 3A5*3/*3 group. At 1 week and 1 month after transplantation, tacrolimus C2 did not show significant difference between the two groups, while at 3 months after transplantation,C2 of CYP 3A5*1/*1+ CYP 3A5*1/*3 group and is significantly lower than the CYP 3A5*3/*3 group(P0.05).C2/dose of CYP 3A5*1/*1+ CYP 3A5*1/*3 group at 1 week, 1 month and 3 months after transplantation were significantly lower than CYP 3A5*3/*3 group (P0.05).Conclusion In renal transplantation, the tacrolimus C2/dose was associated with the CYP 3A5*3 genetic polymorphism.
Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

X Zhang,Zh Liu,Jm Zheng,Zh Chen,Z Tang,Js Chen,Ls Li

DOI: https://doi.org/10.1111/j.1399-0012.2005.00370.x

2005-01-01

Clinical Transplantation

Abstract:Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp, encoded by MDR1) play an important role in the absorption and metabolism of tacrolimus. The objective of this study was to evaluate whether or not CYP3A5*1/*3 or MDR1 C3435T polymorphisms are associated with the tacrolimus concentration per dose.Methods: CYP3A5 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis in 118 Chinese renal transplant patients receiving tacrolimus. Whole blood trough tacrolimus concentration was measured by enzyme-linked immunosorbent assay and dose-adjusted concentration (ng/mL per mg/kg/d) was calculated at 1 wk, 1 month, and 3 months after transplantation.Results: The dose-adjusted concentration of CYP3A5*1/*1 and *1/*3 patients was significantly lower than *3/*3 patients (32.8 +/- 17.7 and 41.6 +/- 15.8 vs. 102.3 +/- 51.2 at 1 wk; 33.1 +/- 7.5 and 46.4 +/- 12.9 vs. 103 +/- 47.5 at 1 month; 35.3 +/- 20.9 and 59.0 +/- 20.6 vs. 150 +/- 85.3 at 3 months after transplantation respectively). At 1 wk, 46% of the CYP3A5*1 allele carriers had a tacrolimus concentration lower than 5 ng/mL and 77% lower than 8 ng/mL, whereas 20% of the *3/*3 patients had a concentration higher than 20 ng/mL. There was a mild difference between *1/*1 homozygotes and *1/*3 heterozygotes at 1 and 3 months after transplantation. No difference was found among the MDR1 genotypes.Conclusion: CYP3A5*1/*3 polymorphisms are associated with tacrolimus pharmacokinetics and dose requirements in renal transplant recipients. Pharmacogenetic methods could be employed prospectively to help initial dose selection and to individualize immunosuppressive therapy.
Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Shi FENG,Xian YANG,Hongfeng HUANG,Jianyong WU,Rending WANG,Jianghua CHEN

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2014.01.007

2014-01-01

Abstract:Objective To study the effects of CYP3A5 * 1 and CYP3A5 * 3 genotypes on tacrolimus dose requirement.Method We tested archival peripheral blood of 69 kidney recipients for CYP3A5 genotyping by polymerase chain reaction.The dose,blood concentrations and dose-normalized blood concentrations of tacrolimus were measured at 1st and 2nd month after the renal transplantation.Result There were 6 cases of CYP3A5 * 1/* 1 (8.7％),22 cases of CYP3A5 * 1/* 3 (31.9％),and 41 cases of CYP3A5 * 3/* 3 (59.4％).At 1st and 2nd month after the renal transplantation,the carriers of CYP3A5 * 1 genotype had a higher mean tacrolimus dose than CYP3A5 * 3/* 3 genotye (both P＜0.000 1),and those of CYP3A5 * 1 genotype had lower mean tacrolimus concentrations than CYP3A5 * 3/* 3 genotye (P=0.020 8,and P =0.019 1 respectively).Meanwhile,the carriers of CYP3A5 * 1 genotype had lower dose-normalized blood concentrations of tacrolimus than CYP3A5 * 3/* 3 genotye (P＜0.000 1) at 1st month after the renal transplantation,as well as at 2nd month after the renal transplantation (P =0.0191).Hepatic and renal function showed no significant effect on tacrolimus dose adjusted concentration at 1st and 2nd month after transplantation.Gender did not show a significant impact on tacrolimus dose.Conclusion CYP3A5 * 1 carriers needhigher tacrolimus dose than CYP3A5 * 3 homozygote to achieve the target blood concentration.CYP3A5 genotyping is a new approach for detecting tacrolimus dose requirement in kidney recipients.
CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298x.2004.04.003

2004-01-01

Abstract:Objective:Tacrolimus is an immunosuppressive drug with narrow window of therapeutic dosage range. The wide interindividual variation of tacrolimus' pharmacokinetics is concerned with its clinical application and efficacy. CYP3A and P-glycoprotein(P-gp, encoded by MDR1) are involved in its pharmocokinetics by their effect on the metabolism of tacrolimus or on the muccosal absorption. In this study, we evaluated whether the CYP3A5 *1/*3 polymorphism or the MDR1 C3435T polymorphism were associated with tacrolimus concentration/dose ratio. Methodology:CYP3A5 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis in 118 adult renal transplant patients receiving tacrolimus. Tacrolimus tough concentration was measured by ELISA and concentration/dose ratio was determined at the 7th day, the end of the 1st month and the end of the 3rd month after renal transplantation. Results:The concentration/dose ratios of CYP3A5 *1/*1 and *1/*3 patients were significantly lower than those of *3/*3 patients at the 7th day, the end of the 1st month and the end of the 3rd month after translation. There was mild difference between *1/*1 homozygotes and *1/*3 heterozygotes at 1 and 3 months after operation. No difference was found among the MDR1 genotypes. Conclusion:CYP3A5 *1/*3 polymorphism are associated with tacrolimus pharmacokinetics and dose requirements in renal transplant recipients. Clinical application of the gene polymorphism and pharmacogenetic studies will be of clinical significance in the individulization of tacrolimus dosage.
Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

张鑫,刘志红,郑敬民,陈朝红,陈强,牛建英,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298x.2003.05.013

2003-01-01

Abstract:Objective: Tacrolimus is an immunosuppressive drug with narrow therapeutic range and wide interindividual variation in its pharmacokinetics. P-glycoprotein(P-gp) and CYP3A play an important role in the absorption or metabolism of tacrolimus. The polymorphism 3435CT of MDR1, the gene encoding P-gp, could influence the expression and activity of P-gp, while it was proved that the activity of CYP3A5 was correlated with the CYP 3AP1 A-44G polymorphism. The aim of this study was to evaluate whether the MDR1 polymorphism or the CYP 3AP1 polymorphism were associated with tacrolimus concentration/dose ratio. Methodology: Forty one lupus nephritis or membranous nephropathy patients treated with tacrolimus were enrolled in this study. Their body weight, dosage and concentration of tacrolimus were observed. CYP 3AP1 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis. Results: According to CYP 3AP1 genotype, the concentration/dose ratio was higher in AA homozygotes than that in the patients with at least one G allele (151.3±93.4, n =21 vs 69.2±39.4, n =20, p 0.001). The difference between MDR1 CC and CT/TT subjects was also statistically significant (73.7±38.2, n =12 vs 126.8±91.3, n =29, p 0.05). Conclusion: CYP 3AP1 A-44G polymorphism and MDR1 C3435T polymorphism are associated with tacrolimus pharmacokinetics and dose requirements. Pharmacogenetic methods could be employed prospectively to help the dose selection and to individualize immunosuppressive therapy according to this information.
Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Zhao JIN,Wei-xia ZHANG,Bing CHEN,An-wei MAO,Hao CHEN,Zhi-dong GU,Wei-min CAI

DOI: https://doi.org/10.3321/j.issn:1001-2494.2008.09.003

2008-01-01

Abstract:OBJECTIVE: To investigate the effect of CYP3A5 and MDR1 on the concentration/dose ratio of tacrolimus in Chinese liver transplant patients. METHODS: Blood samples were collected from liver transplant patients who received tacrolimus . The CYP3A5 and MDR1 genotypes were determined by PCR-RFLP method. Tacrolimus tough concentration was measured by FPIA. The concentration/dose ratio was determined at 7, 14 d and 1 month after liver transplantation. RESULTS: The concentration/dose ratios of patients with CYP3A5 * 1/ * 1 and CYP3A5 * 1/ * 3 carrier were significantly lower than those with CYP3A5 * 3 * 3 patients at 7, 14 d and 1 month after liver transplantation. No difference was found among the MDR1 genotypes. CONCLUSION: CYP3A5 * 3 polymorphism is correlated with the whole blood concentration/dose ratio in Chinese liver transplant patients. Clinical application of pharmacogenetic studies will be significant for the individualization of tacrolimus dosage.
Correction: Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients

Lihui Qu,Yingying Lu,Meike Ying,Bingjue Li,Chunhua Weng,Zhoutao Xie,Ludan Liang,Chuan Lin,Xian Yang,Shi Feng,Yucheng Wang,Xiujin Shen,Qin Zhou,Ying Chen,Zhimin Chen,Jianyong Wu,Weiqiang Lin,Yi Shen,Jing Qin,Hang Xu,Feng Xu,Junwen Wang,Jianghua Chen,Hong Jiang,Hongfeng Huang

DOI: https://doi.org/10.18632/oncotarget.27561

2020-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.18150.].
Systematic review on effects of CYP3A4*1G genetic polymorphism on daily dose of tacrolimus and drug concentration in renal transplant recipients

SHI Wei-long,TANG Hui-lin,ZHAI Suo-di

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2015.04.017

2015-01-01

Abstract:Objective To systematically assess the effects of CYP3A4*1G genetic polymorphism on daily dose of tacrolimus, tacrolimus trough concentration and dose-adjusted trough concentration.Methods The EmBase, PubMed, Cochrane Library, CNKI, WanFang and SinoMed databases were searched, and related literature were manually searched focused on the influence of CYP3A4*1G genetic polymorphism on daily dose of tacrolimus and drug concentrations.The Meta-analysis was per-formed by Revman 5.2 software.Results A total of seven studies ( five papers in Chinese and two papers in English ) were included, involving 750 adult renal transplant recipients.The results of meta -analysis re-vealed that the CYP3A4*1G carriers need higher weight-adjusted daily dose of tacrolimus than the patients carried CYP3A4 * 1/* 1 ( P<0.05) .A subgroup analysis revealed that there was no significant diffe-rence between the two groups two weeks after renal transplant, but at one month and two three months after transplant, the CYP3A4*1G carriers required higher weight-adjusted daily dose of tacrolimus than the patients carried CYP3 A4*1/*1 . Besides, CYP3 A4 *1 G carriers showed a lower tacrolimus trough concentration and dose-ad-justed trough concentration compared with CYP3 A4*1/*1 carriers ( P <0.05 ) . Conclusion CYP3 A4*1 G genetic polymorphism significantly influences the daily dose of tacrolimus and drug concentration in adult renal transplant recipients.
Cyp3a4/5 Polymorphisms Affect The Blood Level Of Cyclosporine And Tacrolimus In Chinese Renal Transplant Recipients

Dan-ying Li,Rui-chen Teng,Huai-jun Zhu,Yun Fang

DOI: https://doi.org/10.5414/CP201836

2013-01-01

International Journal of Clinical Pharmacology and Therapeutics

Abstract:Objective: Both cyclosporine and tacrolimus display a narrow therapeutic index as well as high interindividual pharmacolcinetic variability We approached the effect of the CYP3A4*18B and CYP3A5*3 polymorphisms and haplotypes on the whole blood cyclosporine or tacrolimus concentration in Chinese renal transplant patients during the first month after transplantation. Materials and methods: A total of 83 recipients receiving tacrolimus or cyclosporine was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The whole blood concentration was measured by enzyme-multiplied immunoassay technique. Results: Both CYP3A4*18B and CYP3A5*3 polyraorphisms affected the tacrolimus dose-adjusted trough concentration (C-0/D). The tacrolimus C-0/D) was higher in carriers of haplotype GG compared with the non-carriers. The cyclosporine dose-adjusted 2-hour post-dose concentrations (C2/D), dose-adjusted C-0 + C-2 ((C-0 + C-2)/D) and C-2/C-0 during Days 15 - 21 displayed significant difference among the three genotypes. Statistical difference was observed between CYP3A4*1/*1 and CYP3A4*18B/*18B groups and between CYP3A4*1/*18B and CYP3A4*18B/*18B groups, but no difference was detected between CYP3A4*1/*1 and CYP3A4*1/*18B groups. No difference was found in CO among the three genotypes of CYP3A4*18B polymorphism, and neither CYP3A5*3 polymorphisms nor CYP3A haplotype-derived genotypes affected the cyclosporine dose-adjusted concentration. Conclusions: Genetic polymorphisms of CYP3A5*3 and CYP3A4*18B may be partly responsible in large interindividual variability of cyclosporine and tacrolimus blood levels in Chinese renal transplant patients during the first month after transplantation. A patient carried combined genotype of CYP3A4*1/*1-CY-P3A5*31*3 might require lower tacrolimus doses to achieve target concentration levels. Genotyping of CYP3A4*18B and CYP3A5*3 before transplantation is of benefit in determining a suitable initial dose for each patient.
Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis

Jung Sun Kim,Sunyoung Shim,Jeong Yee,Kyung Hee Choi,Hye Sun Gwak

DOI: https://doi.org/10.3389/fphar.2023.1201083

2023-07-26

Abstract:Purpose: Tacrolimus (Tac) is a widely used immunosuppressive agent in kidney transplantation. Cytochrome P450 (CYP), especially CYP3A4 enzymes are responsible for the metabolism of drugs. However, the correlation between plasma Tac concentration and CYP3A4*22 gene variants is controversial. This meta-analysis aims to evaluate the association between CYP3A4*22 polymorphism and the dose-adjusted trough concentration (C0/D) of Tac in adult kidney transplant patients. Methods: We conducted a literature review for qualifying studies using the PubMed, Web of Science, and Embase databases until July 2023. For the continuous variables (C0/D and daily dose), mean difference (MD) and corresponding 95% confidence intervals (CIs) were calculated to evaluate the association between the CYP3A4 * 22 and Tac pharmacokinetics. We performed an additional analysis on the relationship of CYP3A5*3 with Tac PKs and analyzed the effects of CYP3A4*22 in CYP3A5 non-expressers. Results: Overall, eight eligible studies with 2,683 renal transplant recipients were included in this meta-analysis. The CYP3A4*22 allele was significantly associated with a higher C0/D (MD 0.57 ng/mL/mg (95% CI: 0.28 to 0.86; p = 0.0001) and lower mean daily dose requirement (MD -2.02 mg/day, 95% CI: -2.55 to -1.50; p < 0.00001). An additional meta-analysis demonstrated that carrying the CYP3A5*3 polymorphism greatly impacted Tac blood concentration. From the result with CYP3A5 non-expressers, CYP3A4*22 showed significant effects on the Tac C0/D and dose requirement even after adjusting the effect of CYP3A5*3. Conclusion: Patients with CYP3A4*22 allele showed significantly higher plasma C0/D of Tac and required lower daily dose to achieve the therapeutic trough level after kidney transplantation. These findings of our meta-analysis may provide further evidence for the effects of genetic polymorphism in CYP3A4 on the PKs of Tac, which will improve individualized treatment in a clinical setting.
Association Of Cyp3a4*18b Polymorphisms With The Pharmacokinetics Of Tacrolimus In Chinese Renal Transplant Recipients

Li Danying,Fang Yun,Teng Ruichen

2011-01-01

Abstract:Polymorphisms in the CYP3A4 may play a significant role in individualizing tacrolimus dosage and subsequently the allograft outcome in renal transplant recipients. In the present study, we approached the effect of CYP3A4* 18B polymorphisms on serum tacrolimus concentration in Chinese renal transplant patients during the first month after transplantation. A total of 30 recipients receiving tacrolimus were genotyped by PCR-RFLP, and the C-o of tacrolimus was determined by EMIT. An unpaired T-test was employed to analyze the relationship between CYP3A4* 18B polymorphisms and tacrolimus C/D value. The allele frequency of CYP3A4* 18B was 0. 333, which fits Hardy-Weinberg equilibrium. Patients were classified into two groups: poor metabolizer (PM) homozygous (* 1/* 1) and extensive metabolizer (EM) homozygous (* 1/* 18B and * 18B/* 18B). The C/D value of the two groups were (98. 02 +/- 18. 56)ng/mL and (62. 91 +/- 18. 15) ng/mL(P<0. 01), respectively. The tacrolimus C/D value of the PM group was significantly higher than that of the EM group. In conclusion, the CYP3A4* 18B polymorphisms affects tacrolimus C/D value probably resulting from a higher CYP3A4 enzymatic activity of this allele in Chinese renal transplant patients.
Effects Of The Cyp3a4*1b Genetic Polymorphism On The Pharmacokinetics Of Tacrolimus In Adult Renal Transplant Recipients: A Meta-Analysis

weilong shi,huilin tang,suodi zhai

DOI: https://doi.org/10.1371/journal.pone.0127995

IF: 3.7

2015-01-01

PLoS ONE

Abstract:Background and ObjectiveThe association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial. Therefore, a meta-analysis was employed to evaluate the correlation between the CYP3A4*1B genetic polymorphism and tacrolimus pharmacokinetics at different post-transplantation times in adult renal transplant recipients.MethodsStudies evaluating the CYP3A4*1B genetic polymorphism and tacrolimus pharmacokinetics were retrieved through a systematical search of Embase, PubMed, the Cochrane Library, ClinicalTrials.gov and three Chinese literature databases (up to Sept. 2014). The pharmacokinetic parameters (weight-adjusted tacrolimus daily dose and tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio) were extracted, and the meta-analysis was performed using Stata 12.1.ResultsSeven studies (involving 1182 adult renal transplant recipients) were included in this meta-analysis. For the weight-adjusted tacrolimus daily dose, in all included renal transplant recipients (European & Indian populations), CYP3A4*1/*1 recipients required a significantly lower weight-adjusted tacrolimus daily dose than did CYP3A4* 1B carriers at 7 days (WMD -0.048; 95% CI -0.083 similar to -0.014), 6 months (WMD -0.058; 95% CI -0.081 similar to -0.036) and 12 months (WMD -0.061; 95% CI -0.096 similar to -0.027) post-transplantation. In light of the heterogeneity, the analysis was repeated after removing the only study in an Indian population, and CYP3A4*1/*1 European recipients (mostly Caucasian) required a lower weight-adjusted tacrolimus daily dose within the first year post-transplantation. The tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio (C-0/Dose ratio) was significantly higher in CYP3A4*1/*1 recipients than in CYP3A4*1B carriers at 6 months (WMD 52.588; 95% CI 22.387 similar to 82.789) and 12 months (WMD 62.219; 95% CI 14.218 similar to 110.221) post-transplantation. When the only study in an Indian population was removed to examine European recipients (mostly Caucasian), the significant difference persisted at 1 month, 6 months and 12 months post-transplantation.ConclusionBased on our meta-analysis, the CYP3A4*1B genetic polymorphism affects tacrolimus dose requirements and tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio within the first year post-transplantation in adult renal transplant recipients, especially in European recipients (mostly Caucasian).
Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

Qiaoling Yang,Yan Wang,Xuebin Wang,Ping Wang,Boyu Tan,Yijun Li,Huajun Sun,Wenyan Huang,Hongxia Liu

DOI: https://doi.org/10.3389/fphar.2024.1463595

2024-09-03

Abstract:Background: Tacrolimus is widely used to treat pediatric nephrotic range proteinuria (NRP). Diltiazem, a CYP3A4/5 inhibitor, is often administered with tacrolimus, affecting its pharmacokinetic profile. The impact of this combination on tacrolimus exposure, particularly in CYP3A5*3 genetic polymorphism, remains unclear in pediatric NRP patients. This study aimed to evaluate the effects of diltiazem on tacrolimus pharmacokinetics, focusing on the CYP3A5*3 polymorphism. Methods: We conducted a retrospective clinical study involving pediatric NRP patients, divided into two groups: those receiving tacrolimus with diltiazem and those receiving tacrolimus alone. Propensity score matching (PSM) was used to balance the baseline characteristics between the groups. We compared daily dose-adjusted trough concentrations (C0/D) of tacrolimus in both the original and PSM cohorts. The influence of diltiazem on tacrolimus C0/D, stratified by CYP3A5*3 genetic polymorphism, was assessed in a self-controlled case series study. Results: Before PSM, the tacrolimus C0/D in patients taking diltiazem was significantly higher compared to those with tacrolimus alone (75.84 vs. 56.86 ng/mL per mg/kg, P = 0.034). This finding persisted after PSM (75.84 vs. 46.93 ng/mL per mg/kg, P= 0.028). In the self-controlled case study, tacrolimus C0/D elevated about twofold (75.84 vs. 34.76 ng/mL per mg/kg, P < 0.001) after diltiazem administration. CYP3A5 expressers (CYP3A5*1/*1 and *1/*3) and CYP3A5 non-expressers (CYP3A5*3/*3) experienced a 1.8-fold and 1.3-fold increase in tacrolimus C0/D when combined with diltiazem, respectively. Conclusion: Diltiazem significantly increased tacrolimus C0/D, with CYP3A5*3 expressers showing higher elevations than non-expressers among pediatric NRP patients. These findings highlight the importance of personalized tacrolimus therapy based on CYP3A5*3 genotypes in pediatric patients taking diltiazem.
CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review

Peng Cao,Feilong Zhang,Jiandong Zhang,Xiang Zheng,Zejia Sun,Baozhong Yu,Wei Wang

DOI: https://doi.org/10.1016/j.transproceed.2021.10.031

Abstract:Background: Tacrolimus is a common immunosuppressive for transplantation. The enzyme encoded by the CYP3A5 gene can regulate the metabolism of tacrolimus, and the polymorphism of the CYP3A5 gene regulates the enzyme function. However, its characteristics in Chinese kidney transplant recipients remain unclear. Methods: A computer-based database retrieval included Pubmed, Web of Science, Embase, China National Knowledge Infrastructure, China Biology Medicine Disc, and WanFang databases between January 2010 and December 2020. Search terms included "CYP3A5," "polymorphism," and "renal transplantation." Literature included in this study had sample sizes >130. Genetic testing data of CYP3A5*1/*1, *1/*3, *3/*3 genes were analyzed using a statistical method of meta-analysis to explore the mutation rate of CYP3A5 in Chinese and foreign populations. Results: The frequency of the A allele in the CYP3A5 gene was 23% in all transplant recipients from the 28 included studies. The frequency in Chinese renal transplant recipients was 29%, and it was 30% in renal transplant recipients from other Asian countries but significantly higher than that in Western renal transplant recipients (14%). In subgroup analysis, the frequencies of the A allele in renal transplant recipients in different parts of China were comparable. Conclusions: We found that there were significant differences in CYP3A5 gene polymorphism between Asians and Westerners. There was no significant difference in the frequency of the A allele in CYP3A5 gene among Chinese renal transplant recipients from different parts of China.
Effect of CYP3 A4, CYP3 A5 and ABCB1 Gene Polymorphisms on the Clinical Efficacy of Tacrolimus in the Treatment of Nephrotic Syndrome

Min Li,Min Xu,Wei Liu,Xin Gao

DOI: https://doi.org/10.1186/s40360-018-0202-9

2018-01-01

Abstract:The efficacy of tacrolimus (TAC) is variable in the treatment of nephrotic syndrome (NS), which might be related to genetic variation among patients. Therefore, we aim to investigate the effects of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of TAC in the treatment of NS patients.
CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients

Weimin Cai

2007-01-01

Abstract:AIM: Tacrolimus shows considerable interindividual pharmacokinetic variability, therapeutic drug monitoring of trough blood concentration is necessary to avoid adverse effects. CYP3A5 and P-glycoprotein (P-gp, encoded by MDR1) are involved in tacrolimus' metabolism and absorption process. This study is to investigate whether tacrolimus dosage adjustment is affected by the polymorphism in CYP3A5 and MDR1 in Chinese liver transplant patients. METHODS: Forty-nine liver transplant patients treated with tacrolimus were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was applied to determine the genotype of CYP3A5 and MDR1. Tacrolimus blood tough concentration was measured by FPIA, and concentration/dose ratio(C/D) was investigated at day 7, day 14 and 1 month after liver transplantation. RESULTS: The CD ratios in recipient with CYP3A5*1/*1 (*1/*3) were significantly lower than those of CYP3A5*3/*3 patients after liver transplantation, and the C/D ratios of CYP3A5*1/*1 ,*1/*3 and *3/*3 were shown as follows: 76, 82±18, 164±51 at 7 days; 32, 76±19, 132±31 at 14 days; 36, 65±25, 122±32 at 1 month. No significant difference was found among the MDR1 G2677T/A and C3435T genotype. CONCLUSION: There was no relationship between MDR1 gene polymorphism (C3435T, G2677T/A) and tacrolimus C/D ratio in Chinese liver transplantation patients. CYP3A5 *3 polymorphism is correlated with the whole blood concentration of tacrolimus and dose requirement. The intestinal CYP3A5 plays an important role in the metabolism of orally administered tacrolimus in the first month after liver transplantation.
IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

Mou-ze Liu,Hai-yan He,Yue-li Zhang,Yong-fang Hu,Fa-zhong He,Jian-quan Luo,Zhi-ying Luo,Xiao-ping Chen,Zhao-qian Liu,Hong-hao Zhou,Ming-jie Shao,Ying-zi Ming,Hua-wen Xin,Wei Zhang

DOI: https://doi.org/10.1038/aps.2016.153

IF: 7.169

2017-01-01

Acta Pharmacologica Sinica

Abstract:The highly variable pharmacokinetics and narrow therapeutic window of tacrolimus (TAC) has hampered its clinical use. Genetic polymorphisms may contribute to the variable response, but the evidence is not compelling, and the explanation is unclear. In this study we attempted to find previously unknown genetic factors that may influence the TAC dose requirements. The association of 105 pathway-related single nucleotide polymorphisms (SNPs) with TAC dose-adjusted concentrations (C0/D) was examined at 7, 30 and 90 d post-operation in 382 Chinese kidney transplant recipients. In CYP3A5 non-expressers, the patients carrying the IL-3 rs181781 AA genotype showed a significantly higher TAC logC0/D than those with the AG genotype at 30 and 90 d post-operation (AA vs AG, 2.21±0.06 vs 2.01±0.03, P =0.004; and 2.17±0.06 vs 2.03±0.03, P =0.033, respectively), and than those with the GG genotype at 30 d (AA vs GG, 2.21±0.06 vs 2.04±0.03, P =0.011). At 30 d, the TAC logC0/D in the grouped AG+GG genotypes of CTLA4 rs4553808 was significantly lower than that in the AA genotype ( P =0.041) in CYP3A5 expressers, but it was higher ( P =0.008) in the non-expressers. We further validated the influence of CYP3A5 rs776746, CYP3A4 rs2242480 and rs4646437 on the TAC C0/D; other candidate SNPs were not associated with the differences in TAC C0/D. In conclusion, genetic polymorphisms in the immune genes IL-3 rs181781 and CTLA4 rs4553808 may influence the TAC C0/D. They may, together with CYP3A5 rs776746, CYP3A4 rs2242480 and rs4646437, contribute to the variation in TAC dose requirements. When conducting individualized therapy with tacrolimus, these genetic factors should be taken into account.

CYP3A5 and CYP3A7 Genetic Polymorphisms Affect Tacrolimus Concentration in Pediatric Patients with Nephrotic Range Proteinuria

Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome.

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis

Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Correction: Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients

Systematic review on effects of CYP3A4*1G genetic polymorphism on daily dose of tacrolimus and drug concentration in renal transplant recipients

Cyp3a4/5 Polymorphisms Affect The Blood Level Of Cyclosporine And Tacrolimus In Chinese Renal Transplant Recipients

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis

Association Of Cyp3a4*18b Polymorphisms With The Pharmacokinetics Of Tacrolimus In Chinese Renal Transplant Recipients

Effects Of The Cyp3a4*1b Genetic Polymorphism On The Pharmacokinetics Of Tacrolimus In Adult Renal Transplant Recipients: A Meta-Analysis

Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review

Effect of CYP3 A4, CYP3 A5 and ABCB1 Gene Polymorphisms on the Clinical Efficacy of Tacrolimus in the Treatment of Nephrotic Syndrome

CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients